Investigating how death receptor 4 can improve cancer treatment for lung cancer patients
Modulation of death receptor 4 in EGFR-targeted cancer therapy
This study is looking at ways to make cancer treatments better for people with non-small cell lung cancer by focusing on certain changes in a gene called EGFR, and it hopes to find new methods to help overcome challenges with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10653881 on NIH RePORTER |
What this research studies
This research focuses on enhancing cancer therapy for patients with non-small cell lung cancer (NSCLC) by targeting specific mutations in the epidermal growth factor receptor (EGFR). It aims to understand how the death receptor 4 (DR4) can be modulated to overcome resistance to current EGFR-targeted therapies. By examining the effects of various EGFR inhibitors on DR4 levels and their relationship with cancer cell death, the research seeks to develop new strategies that could improve treatment outcomes for patients. The approach involves both laboratory experiments with cancer cell lines and potential implications for clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have specific EGFR mutations.
Not a fit: Patients with lung cancer who do not have EGFR mutations or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer patients who have developed resistance to existing therapies.
How similar studies have performed: Previous research has shown promising results in targeting EGFR mutations in lung cancer, but the specific modulation of DR4 in this context is a novel approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Sun, Shi-Yong — Emory University
- Study coordinator: Sun, Shi-Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.